Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sagility India Limited (SAGILITY.NS)
Bengaluru, IN
Headquartered in Bengaluru, India, and established in 2021, Sagility India Limited specializes in providing comprehensive business process management (BPM) services. The company primarily caters to clients within the healthcare and insurance industries across multiple international markets, including India, Jamaica, the Philippines, the United States, and Colombia. Its extensive range of services encompasses claims management and cost containment, member engagement and enrollment, benefits plan construction, and ensuring payment integrity and accurate billing. Additionally, Sagility offers credentialing, clinical and case management, provider solutions, robust analytics, front and back-office support, and data management. The company further delivers utilization and care management, population health management, and a full spectrum of revenue cycle management functions, such as financial clearance, medical coding, billing, and accounts receivable follow-up. Sagility India Limited operates as a subsidiary of Sagility B.V.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.31% | -5.54% | -2.33% | -8.19% | -17.59% | -19.40% | -9.38% | +42.81% | +42.81% | +42.81% | +42.81% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+29.1% ★ Q1'26: +29.1% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%+69.2% ★ Q1'26: +43.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+13.4% Q1'26: +21.2% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+17.7% ★ Q1'26: +17.8% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+9.6% ★ Q1'26: +10.4% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+1.4% Q1'26: -1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.63× Q1'26: 0.57× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2025 actual |
Mar 2026 9 Rev. Ana. 6 EPS Ana. |
Mar 2027 8 Rev. Ana. 9 EPS Ana. |
Mar 2028 9 Rev. Ana. 9 EPS Ana. |
Mar 2029 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
55.70B
est: 55.82B (-0.2%)
|
72.15B
71.29B – 75.15B
+29.3% YoY
|
84.64B
83.64B – 86.31B
+17.3% YoY
|
95.16B
95.05B – 95.26B
+12.4% YoY
|
106.57B
106.54B – 106.61B
+12.0% YoY
|
| EBITDA |
12.98B
est: 12.67B (+2.4%)
|
16.38B
16.19B – 17.06B
+29.3% YoY
|
19.22B
18.99B – 19.60B
+17.3% YoY
|
21.61B
21.58B – 21.63B
+12.4% YoY
|
24.20B
24.19B – 24.21B
+12.0% YoY
|
| EBIT |
8.31B
est: 6.26B (+32.8%)
|
8.09B
7.99B – 8.42B
+29.3% YoY
|
9.49B
9.38B – 9.67B
+17.3% YoY
|
10.67B
10.65B – 10.68B
+12.4% YoY
|
11.95B
11.94B – 11.95B
+12.0% YoY
|
| Net Income |
5.39B
est: 6.10B (-11.6%)
|
9.25B
8.42B – 11.23B
+51.7% YoY
|
12.45B
11.25B – 13.66B
+34.7% YoY
|
14.59B
13.62B – 15.56B
+17.1% YoY
|
15.21B
14.85B – 17.67B
+4.3% YoY
|
| SGA |
2.13B
est: 1.57B (+35.2%)
|
2.03B
2.01B – 2.12B
+29.3% YoY
|
2.39B
2.36B – 2.43B
+17.3% YoY
|
2.68B
2.68B – 2.68B
+12.4% YoY
|
3.00B
3.00B – 3.00B
+12.0% YoY
|
| EPS |
1.17
est: 1.30 (-9.9%)
|
2.13
1.80 – 2.40
+64.0% YoY
|
2.70
2.41 – 2.92
+26.8% YoY
|
3.13
2.92 – 3.33
+15.9% YoY
|
3.45
3.18 – 3.78
+10.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ramesh Gopalan | MD, Group Chief Executive Officer & Director | 69M | male |
| Srinivas Rathnam Mattapalli | Executive Vice President & Group Chief Financial Officer | 19M | male |
| Satishkumar Sakharayapattana Seetharamaiah | Associate Vice President, Company Secretary & Compliance Officer | 7M | male |
| Madan Moudgal | Executive Vice President & Chief Digital Officer | — | male |
| Manish Dubey | Senior Vice President & Global Head of Enterprise Tech | — | male |
| Mohit Saxena | Executive Vice President & Chief Delivery Officer | — | male |
| Siby Joy | Executive VP of Client Services | — | male |
| Anand Biradar | Senior Vice President of GTM Strategy, Enablement & Enterprise Transformation | — | male |
| Tina Vas | Executive Vice President & Chief Human Resources Officer | — | female |
| Anand Natampalli | Executive VP of Client Services | — | male |
| Daniel Bailey | Executive Vice President & Global General Counsel | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SAGILITY.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
